SCHEMBL1572288

SCHEMBL1572288

C#Cc1ccc2nc(Nc3cc(OCCN4CCCC4)ccc3-c3cnn(C)c3)ncc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 1/20 0.51
▸ FGFR1 P11362 1/20 0.40
▸ CLK2 P49760 1/20 0.40
▸ CLK3 P49761 1/20 0.40
▸ GSK3B P49841 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ SRC P12931 7/20 0.40
▸ ACHE P22303 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ GRM4 Q14833 1/20 0.39
▸ AXL P30530 1/20 0.38
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ TTK P33981 1/20 0.38
▸ IGF1R P08069 5/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ YES1 P07947 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ PDGFRB P09619 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1572062 0.85 BRAF (0.53) BRAFFGFR1SRCAXLABL1
SCHEMBL13336034 0.75 MAP4K1 (0.42) BRAFGSK3BDYRK1AKDR
SCHEMBL1571160 0.75 BRAF (0.51) BRAFFGFR1SRCAXLABL1
SCHEMBL13336031 0.74 MAP4K1 (0.42) BRAFGSK3BDYRK1AACHEKDR
SCHEMBL13336194 0.74 MAP4K1 (0.41) BRAFFGFR1CCNA2CDK2TTK
SCHEMBL1571456 0.73 MAP4K1 (0.40) BRAFFGFR1CCNA2CDK2TTK
SCHEMBL1571949 0.73 GSK3B (0.42) BRAFFGFR1CLK2CLK3GSK3B
SCHEMBL13363267 0.72 BRAF (0.54) BRAFFGFR1SRCACHEAXL
SCHEMBL1571076 0.70 PDK2 (0.41) BRAFFGFR1KDR
SCHEMBL13225920 0.70 MAP4K1 (0.43) BRAFCCNA2CDK2TTKIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307385-A1 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES Novartis AG (CH) 2011-04-13 — — EP disclosed
WO-2009153313-A1 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2009-12-23 — — WO disclosed
Send feedback